TY - JOUR
T1 - Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma
AU - Hahn, Seung Min
AU - Kim, Hyo Sun
AU - Kim, Dong Joon
AU - Lee, Sung Chul
AU - Lyu, Chuhl Joo
AU - Han, Jung Woo
N1 - Publisher Copyright:
© 20162016 Taylor & Francis Group, LLC.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2016/1/2
Y1 - 2016/1/2
N2 - The recent trend of treatment for retinoblastoma is to salvage the eye globes as well as achieving patients survival. Intra-arterial chemotherapy (IAC) is one of the current standard treatment; however, it cannot exclude the risk of occult micrometastases in the central nervous system in advanced-stage retinoblastoma. Alternate fashion of intravenous chemotherapy (IVC) and IAC strategy was developed to increase the eye salvage rate and to reduce the metastatic risk. Between January 2012 and December 2014, 13 eyes of 12 patients with newly diagnosed retinoblastoma received alternate chemotherapy using IVC and IAC in Yonsei Cancer Center. Eye salvage rate was assessed by the eye preservation time, which was defined as the duration from the diagnosis to the time of enucleation. Total 13 eyes were classified according to the International Classification of Retinoblastoma (ICRB) as group B (n = 1, 7.7%), group C (n = 2, 15.4%), group D (n = 5, 38.5%), or group E (n = 5, 38.5%). IAC was performed, 3 to 5 times (median: 4 times) for each eye, total 54 times. Five to 15 courses (median: 8 courses) of systemic chemotherapy were performed in the patients. During the median follow-up period of 30.4 months, overall eye salvage rate was 63.9 ± 14.7%. All patients survived. The treatment was tolerable without significant complications. These results showed that primary alternate IVC-IAC was tolerable and effective for retinoblastoma.
AB - The recent trend of treatment for retinoblastoma is to salvage the eye globes as well as achieving patients survival. Intra-arterial chemotherapy (IAC) is one of the current standard treatment; however, it cannot exclude the risk of occult micrometastases in the central nervous system in advanced-stage retinoblastoma. Alternate fashion of intravenous chemotherapy (IVC) and IAC strategy was developed to increase the eye salvage rate and to reduce the metastatic risk. Between January 2012 and December 2014, 13 eyes of 12 patients with newly diagnosed retinoblastoma received alternate chemotherapy using IVC and IAC in Yonsei Cancer Center. Eye salvage rate was assessed by the eye preservation time, which was defined as the duration from the diagnosis to the time of enucleation. Total 13 eyes were classified according to the International Classification of Retinoblastoma (ICRB) as group B (n = 1, 7.7%), group C (n = 2, 15.4%), group D (n = 5, 38.5%), or group E (n = 5, 38.5%). IAC was performed, 3 to 5 times (median: 4 times) for each eye, total 54 times. Five to 15 courses (median: 8 courses) of systemic chemotherapy were performed in the patients. During the median follow-up period of 30.4 months, overall eye salvage rate was 63.9 ± 14.7%. All patients survived. The treatment was tolerable without significant complications. These results showed that primary alternate IVC-IAC was tolerable and effective for retinoblastoma.
UR - http://www.scopus.com/inward/record.url?scp=84959043055&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959043055&partnerID=8YFLogxK
U2 - 10.3109/08880018.2015.1135363
DO - 10.3109/08880018.2015.1135363
M3 - Article
C2 - 26901285
AN - SCOPUS:84959043055
VL - 33
SP - 74
EP - 82
JO - Pediatric Hematology and Oncology
JF - Pediatric Hematology and Oncology
SN - 0888-0018
IS - 1
ER -